NxStage Medical (NASDAQ:NXTM) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report released on Friday.

A number of other analysts have also recently weighed in on the company. BidaskClub cut NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, July 20th. Zacks Investment Research cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $30.00.

Shares of NASDAQ NXTM opened at $27.99 on Friday. The firm has a market capitalization of $1.83 billion, a P/E ratio of -127.23 and a beta of -0.06. NxStage Medical has a one year low of $22.70 and a one year high of $28.75.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Tuesday, August 7th. The medical device company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $106.97 million during the quarter, compared to analyst estimates of $105.35 million. NxStage Medical had a negative return on equity of 7.02% and a negative net margin of 3.67%. Research analysts predict that NxStage Medical will post -0.02 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. NumerixS Investment Technologies Inc bought a new stake in NxStage Medical in the second quarter valued at $122,000. Steward Partners Investment Advisory LLC grew its holdings in shares of NxStage Medical by 714.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after purchasing an additional 5,000 shares during the last quarter. Keybank National Association OH bought a new stake in shares of NxStage Medical during the second quarter worth $212,000. Quantitative Systematic Strategies LLC bought a new stake in shares of NxStage Medical during the second quarter worth $216,000. Finally, Janus Henderson Group PLC bought a new stake in shares of NxStage Medical during the second quarter worth $234,000. Hedge funds and other institutional investors own 83.12% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Featured Article: How is inflation measured?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.